This article describes the clinical data that led to approval of these B-cell receptor inhibitors for the treatment of CLL, and highlights newer agents in clinical development that target the same kinases as the currently available therapies.
Deepa Jeyakumar, MD
Advertisement
Articles by Deepa Jeyakumar, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Tocilizumab Supports Outpatient Bispecific Antibody Use in Multiple Myeloma
2
GLP-1 Receptor Agonists May Improve Survival, Reduce irAEs in ICI-Treated Patients
3
Perioperative Apalutamide Shifts Standard in Localized, High-Risk Prostate Cancer
4
ASCENT-04 Subgroup Analysis Yields Consistent PFS Benefits in Metastatic TNBC
5